12:39 PM EST - HAVN Life Sciences : Announces a partnership with TheraPsil - a non-profit coalition made up of healthcare professionals, patients, community members, and advocates dedicated to helping Canadians in medical need access legal psilocybin-assisted psychotherapy and GMP-quality psilocybin. Under the Partnership, TheraPsil will support prescribing healthcare professionals in requesting psilocybin from HAVN Life, and other licensed dealers enrolled in TheraPsil's "Project Solace", through the Special Access Program. Health Canada has designated the Special Access Program, along with clinical trials, as a preferred pathway for patients to access psilocybin for medical purposes. HAVN Life Sciences
shares C.HAVN are trading -8.33% at $0.05.
